Author: Zacks Small Cap Research

12313710 / 1368 POSTS
By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Business Update Pivoting to Acute Pain Management for Otenaproxesul On October 14, 2021, Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE.TO) provided an update on the deve ...
By T. Moore, CFA NASDAQ:SYTA READ THE FULL SYTA RESEARCH REPORT Business News Update Siyata Mobile Inc. (Siyata Mobile Inc. (NASDAQ:SYTA ) announced weak June Quarter revenues due to a customer refund and weakness form the pandemic. Revenues of $0.4 ...
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Type A Meeting Update Protalix Biotherapeutics, Inc. (NYSE:PLX) updated stakeholders on the regulatory pathway forward for PRX-102. The company is advancing the candidate indicated ...
By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Fiscal Year 2021 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced fiscal year 2021 financial and operational results in a September 29thpress ...
By Beth Senko, CFA OTC:UCASU READ THE FULL UCASU RESEARCH REPORT UC Asset continues to diversify its real estate investment strategies. On September 29, the Company unveiled a new strategy to invest in land and above-ground-properties for cannabis g ...
By M. Marin NYSE:TRC READ THE FULL TRC RESEARCH REPORT Tejon Ranch Company (NYSE:TRC) announced recently that a federal court has upheld an earlier ruling in TRC’s favor regarding its development plans. Objections raised in a lawsuit filed by the Tuc ...
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Rapid Resolution of Symptoms in Phase 2 Trial On October 4, 2021, ContraFect Corp. (NASDAQ:CFRX) announced new data from the company’s Phase 2 clinical trial of exebac ...
By David Bautz, PhD OTC:VIVXF READ THE FULL VIVXF RESEARCH REPORT Business Update Landmark Deal with AB Vista On October 1, 2021, Avivagen, Inc. (OTC:VIVXF) announced a landmark eight-year deal with AB Vista, a diversified international food ingredie ...
By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT Initiating Coverage We are initiating coverage of Celsion Corporation (NASDAQ:CLSN) with a valuation of $3.50. Celsion is a biopharmaceutical company developing DNA-based immunothera ...
By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT In an October 5th press release, Lexaria Biosciences (NASDAQ:LEXX) presented impressive results in its nicotine animal study NIC-A21-1. Lexaria has worked with both Altria Group ...
12313710 / 1368 POSTS